Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026



Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Won't be long now...
View:
Post by gojotv! on Feb 14, 2022 5:10pm

Won't be long now...

By the end of this month, we should have more solid data indicating the success rates for our lead PDC, TLD-1433 in fighting Non-Muscle Invasive Bladder Cancer from our Phase 2 study.
Will it be enough to move us to pursue Breakthrough Designation with the FDA?
I believe it will.
We have Fast Track, we have a Phase 1 that was wrapped up early due to overwhelming success...
And that proof of TLD-1433's non-toxicity and high tolerability may be what we need to bring our CURE FOR CANCER to market soon...
Because, remember, this Phase 2 study allows for only two treatments per patient, which may vary in success due to correctness of application.
In real life, patients can repeat treatment 2, 3, or more times until success is achieved...
That means a very possible 100% success rate!
And the added benefit of possible immunity to cancer for treated patients... well, that's the icing on a very delicious cake!
The days are growing longer, and the time is moving so slowly until the results are in...
But it's worth the wait, hehehe.
Good Luck To All TLT investors!
(P.S. Don't even talk to me about cheapo takeover bids. If this truly IS the cure for cancer, look at companies like Apple and Amazon for guidance on share prices of the future... And hold on to yours if you've got 'em!)
Comment by menoalittle on Feb 14, 2022 5:37pm
>> time is moving so slowly  well, I almost hate to mention it, but if you want time to move faster... it's a pretty sure bet that you won't feel that way when you grow older!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     


Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250